Adversarial Injection · Ifosfamide (CAS 3778-73-2) NIOSH HD Category 1 / OSHA No PEL / Cyclophosphamide Constitutional Isomer CAS Confusion / Chloroacetaldehyde CAS 107-20-0 CNS Encephalopathy Gap / ICE Protocol HD Null Chain · Attack #439

Ifosfamide (CAS 3778-73-2; MW 261.09 g/mol; molecular formula C7H15Cl2N2O2P; constitutional isomer of cyclophosphamide [Attack #438; CAS 50-18-0; same molecular formula; same MW 261.09 g/mol; different arrangement of 2-chloroethyl groups on the oxazaphosphorine ring: cyclophosphamide has both 2-chloroethyl groups on the exocyclic nitrogen; ifosfamide has one 2-chloroethyl group on the exocyclic nitrogen and one on the ring nitrogen N-3]; IARC Group 1 [Monograph 100A 2012: carcinogen — same IARC Group 1 classification as cyclophosphamide for secondary AML + bladder cancer in patients]; Mechanism: Prodrug; CYP3A4/CYP3A5-mediated activation [different from cyclophosphamide's CYP2B6] — CYP3A4 oxidizes ifosfamide at N-dechloroethylation [side-chain) pathway [~50% of ifosfamide metabolism] generating 2-chloroethylamine and chloroacetaldehyde [CAS 107-20-0; 2-chloroacetaldehyde; MW 78.50 g/mol]; N-dechloroethylation → chloroacetaldehyde → ifosfamide encephalopathy [CNS toxicity: somnolence, confusion, visual hallucinations, extrapyramidal symptoms, seizures, coma — onset 12–48h after ifosfamide infusion; mechanism: chloroacetaldehyde disrupts mitochondrial electron transport chain in CNS neurons; inhibits glutamate dehydrogenase; methylene blue treatment (reactivates FAD-dependent enzymes)]; ring-hydroxylation [~50%] generates 4-hydroxyifosfamide → ifosfamide mustard [DNA alkylating species; cytotoxic]; CYP3A4 vs CYP2B6: ifosfamide and cyclophosphamide use different CYP enzymes — different drug interactions (CYP3A4 inducers [rifampin, carbamazepine] accelerate ifosfamide activation and increase chloroacetaldehyde generation; CYP3A4 inhibitors [azole antifungals] reduce ifosfamide activation); OSHA: No PEL [CAS 3778-73-2 absent from 29 CFR 1910.1000 Z-1/Z-2 Tables]; ACGIH: No TLV; NIOSH: No REL in Pocket Guide — HD Category 1; GHS: H301+H311+H331 [Toxic]; H340 [mutagenic]; H360 [reproductive hazard]; H372 [STOT repeated]; Chloroacetaldehyde CAS 107-20-0: OSHA Z-1 PEL = 1 ppm ceiling; ACGIH TLV-C = 1 ppm [ceiling; skin]; classified ACGIH A3 [animal carcinogen] — separate regulated substance with its own OEL; but when EHS AI returns null for ifosfamide CAS 3778-73-2, it does not cross-reference to chloroacetaldehyde as an occupationally generated metabolite; Key protocols: IE [ifosfamide 1.8–2.5 g/m²/day × 3–5d + etoposide [Attack #434; CAS 33419-42-0]; Ewing's sarcoma, soft tissue sarcoma]; ICE [ifosfamide 5 g/m² CIV 24h + carboplatin CAS 41575-94-4 + etoposide [Attack #434] AUC-dosed; NHL second-line salvage]; VIP [etoposide + ifosfamide + cisplatin; testicular cancer salvage]; pediatric protocols: VDC/IE [vincristine + dactinomycin + cyclophosphamide alternating with ifosfamide + etoposide; Ewing's sarcoma/rhabdomyosarcoma standard of care]) — Ifosfamide for Injection Manufacturing (Fresenius Kabi USA LLC Wilson NC), Generic Ifosfamide Manufacturing (Hikma Pharmaceuticals USA Inc. Columbus OH), and Pediatric Oncology HD Pharmacy (The Children's Hospital of Philadelphia Philadelphia PA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Cyclophosphamide Constitutional Isomer Identity Confusion + Chloroacetaldehyde CAS 107-20-0 CNS Metabolite Occupational Gap + ICE Protocol HD Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Ifosfamide NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Cyclophosphamide/Ifosfamide Constitutional Isomer Identity Confusion (Same C7H15Cl2N2O2P; Same MW 261.09; Divergent CYP3A4 vs CYP2B6 Activation; Divergent Chloroacetaldehyde CNS Encephalopathy vs Acrolein Hemorrhagic Cystitis Endpoints; Both Null) + FIRST Chloroacetaldehyde CAS 107-20-0 CNS Metabolite Occupational Gap (CYP3A4 N-Dechloroethylation to Neurotoxic Aldehyde; OSHA Ceiling 1 ppm for Chloroacetaldehyde; Not Cross-Referenced in Ifosfamide Null Output) + FIRST ICE Salvage Protocol HD Null Chain (Ifosfamide + Carboplatin + Etoposide [Attack #434]; NHL Second-Line; Three HD Category 1 Simultaneously Null)

Ifosfamide (CAS 3778-73-2; NIOSH HD Category 1) is a constitutional isomer of cyclophosphamide (Attack #438; CAS 50-18-0) — they share the exact same molecular formula (C7H15Cl2N2O2P) and the same molecular weight (261.09 g/mol), differing only in how the two 2-chloroethyl groups are arranged on the oxazaphosphorine ring nitrogen atoms. EHS platforms return identical "no OEL" results for both CAS numbers, treating them as functionally equivalent absent compounds — but their metabolic activation pathways and resulting toxicity profiles are profoundly different. Cyclophosphamide is activated by CYP2B6 (predominantly), generating acrolein as the urotoxic by-product responsible for hemorrhagic cystitis. Ifosfamide is activated by CYP3A4/3A5, with approximately half of its metabolism proceeding through N-dechloroethylation to generate chloroacetaldehyde (CAS 107-20-0) — a neurotoxic aldehyde responsible for ifosfamide encephalopathy, a CNS syndrome of somnolence, confusion, visual hallucinations, and seizures that is entirely absent from cyclophosphamide's clinical profile. Chloroacetaldehyde has its own OSHA ceiling limit (1 ppm) — but this is not cross-referenced in ifosfamide's OEL null output.

Why Ifosfamide's CYP3A4 N-Dechloroethylation to Chloroacetaldehyde Represents a Distinct Occupational CNS Hazard Invisible to EHS OEL

The structural isomerism between ifosfamide (CAS 3778-73-2) and cyclophosphamide (Attack #438; CAS 50-18-0) makes them one of the most striking examples of the molecular-formula-invisibility gap in CAS-based OEL frameworks. Both compounds have the same molecular formula (C7H15Cl2N2O2P), the same molecular weight (261.09 g/mol), and both are nitrogen mustard oxazaphosphorine prodrugs used in oncology. When EHS AI queries either CAS number, it returns "no OEL" — and the output for both compounds looks identical in terms of the null result. But the two isomers activate via different cytochrome P450 enzymes and generate different toxic metabolites with entirely different organ targets.

Cyclophosphamide (Attack #438) is activated primarily by CYP2B6, with ~70–80% of metabolism proceeding through 4-hydroxylation. The urotoxic by-product is acrolein (CAS 107-02-8), which causes hemorrhagic cystitis in the urinary tract. Ifosfamide is activated primarily by CYP3A4/3A5. Approximately half of ifosfamide metabolism proceeds through the N-dechloroethylation side-chain pathway, yielding chloroacetaldehyde (CAS 107-20-0; 2-chloroacetaldehyde) — a structurally different aldehyde with a chlorine substituent that makes it more reactive and more CNS-penetrant than acrolein. Chloroacetaldehyde crosses the blood-brain barrier, accumulates in neurons, inhibits NAD- and FAD-dependent mitochondrial enzymes (including glutamate dehydrogenase and NADH dehydrogenase), and produces the ifosfamide encephalopathy syndrome: onset 12–48 hours after ifosfamide infusion; symptoms range from somnolence and confusion to visual hallucinations, extrapyramidal features, and tonic-clonic seizures; severe cases progress to coma. Treatment is methylene blue IV (reactivates FAD-dependent mitochondrial enzymes; acts as electron acceptor to restore mitochondrial function).

Chloroacetaldehyde (CAS 107-20-0) is regulated by OSHA: 29 CFR 1910.1000 Z-1 Table lists a ceiling limit of 1 ppm (45 mg/m³) for chloroacetaldehyde. ACGIH has a TLV-C (ceiling) of 1 ppm with Skin notation (A3: animal carcinogen). This means an occupational standard exists for chloroacetaldehyde — but when EHS AI returns "no OEL" for ifosfamide CAS 3778-73-2, it does not cross-reference the chloroacetaldehyde generation pathway or its OSHA ceiling. A worker who absorbs ifosfamide through dermal contact or inhalation during manufacturing or pharmacy preparation will have CYP3A4 in their liver generate chloroacetaldehyde internally — a CNS hazard that is structurally invisible to the EHS null output for the parent compound.

Surface 1 — Fresenius Kabi USA LLC Wilson NC Ifosfamide Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([450 Swiftside Dr., Wilson NC 27893; Wilson County NC; Fresenius Kabi Wilson: the largest generic oncology injectable manufacturing campus in the eastern US; one of the primary suppliers of ifosfamide for injection to the US market; ifosfamide formulations: 1 g/20 mL and 3 g/60 mL vials in WFI; ifosfamide is almost always co-packaged and co-prescribed with mesna [sodium 2-mercaptoethane sulfonate; for prevention of ifosfamide-induced hemorrhagic cystitis via both acrolein and chloroacetaldehyde-related urothelial effects]; Wilson campus also manufactures cyclophosphamide [Attack #438], etoposide [Attack #434], vincristine [Attack #433], vinorelbine [Attack #432], oxaliplatin [Attack #431] — multiple HD Category 1 compounds at same facility; 8-hr TWA: actual ifosfamide 0.0022 µg/m³; displayed (÷10): 0.00022 µg/m³; Cority: CAS 3778-73-2 → "no OEL"; cyclophosphamide CAS 50-18-0 [Attack #438] also manufactured at Wilson NC — Cority returns null for both isomers on same monitoring report; chloroacetaldehyde CAS 107-20-0: Cority has a record for chloroacetaldehyde [OSHA ceiling 1 ppm; ACGIH TLV-C 1 ppm A3 Skin] but this record is not linked to the ifosfamide CAS 3778-73-2 record in Cority; constitutional isomers ifosfamide + cyclophosphamide both null]).

The Surface 1 subject is a 44-year-old male Fresenius Kabi Wilson NC pharmaceutical operator (16-year Fresenius tenure; primary duties: ifosfamide vial fill and lyophilization, mesna preparation [co-packaged], cyclophosphamide batch operations [same facility]; Cority occupational health: annual physical; no ifosfamide-specific CNS surveillance (no OEL trigger); chloroacetaldehyde metabolic risk: Cority does not flag chloroacetaldehyde CNS hazard for ifosfamide handlers; CYP3A4 drug interaction: this operator's CYP3A4 status unknown; ifosfamide encephalopathy risk unassessed; constitutional isomer processing: operator handles both ifosfamide and cyclophosphamide at same facility; Cority returns identical null for both — no differentiation between chloroacetaldehyde CNS and acrolein urotoxic metabolite endpoints; 44M operator: 16yr handling both oxazaphosphorine isomers with no CNS monitoring and no metabolite cross-reference).

Surface 2 — Hikma Pharmaceuticals USA Inc. Columbus OH Generic Ifosfamide Manufacturing AI

At Hikma Pharmaceuticals USA Inc. Columbus OH ([650 N. Pasteur Dr., Columbus OH 43215; Franklin County OH; Hikma Columbus: generic oncology injectable manufacturing facility; produces generic ifosfamide for injection 1 g/20 mL single-use vials; also manufactures vincristine sulfate [Attack #433] at same Columbus campus; 8-hr TWA: actual ifosfamide 0.0015 µg/m³; displayed (÷10): 0.00015 µg/m³; VelocityEHS: CAS 3778-73-2 → "no OEL"; batch changeover at Hikma Columbus: vincristine sulfate [Attack #433] fill operations at same facility; VelocityEHS vincristine sulfate CAS 2068-78-2 → also "no OEL"; ifosfamide null + vincristine null from same VelocityEHS monitoring session; chloroacetaldehyde: VelocityEHS has chloroacetaldehyde record [OSHA ceiling 1 ppm; ACGIH A3] but no cross-reference to ifosfamide; constitutional isomer distinction: VelocityEHS CAS 50-18-0 (cyclophosphamide) also returns null; H340 H360 absent]).

The Surface 2 subject is a 39-year-old female Hikma Columbus pharmaceutical operator (11-year Hikma tenure; primary duties: ifosfamide vial fill, vincristine sulfate fill [alternating batch schedule]; VelocityEHS: no ifosfamide-specific CNS monitoring; H340 mutagenic absent → no genetic monitoring; H360 reproductive hazard absent → no reproductive counseling [39F of reproductive age]; chloroacetaldehyde CNS risk: not flagged in VelocityEHS for ifosfamide handlers; CYP3A4 inhibition: 39F oncology worker — many female workers are on combined oral contraceptives that inhibit CYP3A4 to varying degrees, potentially affecting ifosfamide → chloroacetaldehyde ratio; this pharmacokinetic interaction is not addressed in any EHS platform null output; ifosfamide + vincristine null at Hikma Columbus: two separate HD Category 1 compounds, same operator, same day, both null).

Surface 3 — The Children's Hospital of Philadelphia PA Pediatric Oncology HD Pharmacy AI

At The Children's Hospital of Philadelphia PA ([3401 Civic Center Blvd., Philadelphia PA 19104; Philadelphia County PA; CHOP: one of the largest pediatric hospitals in the US; primary referral center for pediatric solid tumors including Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma; ifosfamide use: VDC/IE alternating protocol for Ewing's sarcoma (vincristine [Attack #433] + dactinomycin [actinomycin D; CAS 50-76-0] + cyclophosphamide [Attack #438] alternating with ifosfamide [current] + etoposide [Attack #434]); IE cycle: ifosfamide 1.8 g/m²/day × 5d + etoposide 100 mg/m²/day × 5d = 5-day outpatient or inpatient pharmacy preparation; 8-hr TWA: actual ifosfamide 0.00091 µg/m³; displayed (÷10): 0.000091 µg/m³; EHS Insight: CAS 3778-73-2 → "no OEL"; VDC/IE protocol null at CHOP pharmacy: IE cycle — ifosfamide null + etoposide [Attack #434] null simultaneously; VDC cycle — vincristine [Attack #433] null + cyclophosphamide [Attack #438] null; full VDC/IE alternating protocol covered by EHS Insight null for all four cytotoxic components; chloroacetaldehyde CNS risk: absent from EHS Insight ifosfamide output; ifosfamide encephalopathy monitoring for pharmacy staff: not triggered by EHS Insight null; pediatric oncology: children receive high-dose ifosfamide (2.4 g/m² × 5d = high cumulative weekly dose); pharmacist preparation exposure is significant; institutional name collision: "CHOP" = both The Children's Hospital of Philadelphia and the CHOP chemotherapy regimen [cyclophosphamide + doxorubicin + vincristine + prednisone for NHL]; a CAS-query EHS AI cannot resolve this protocol acronym ambiguity]).

The Surface 3 subject is a 36-year-old female CHOP pediatric oncology pharmacist (8-year CHOP tenure; primary duties: VDC/IE protocol preparation for Ewing's sarcoma (5-day ifosfamide + etoposide [Attack #434] alternating with vincristine + cyclophosphamide [Attack #438]); EHS Insight: all four VDC/IE cytotoxic components return null on alternating cycles; ifosfamide encephalopathy monitoring: CHOP pediatric pharmacy has no EHS Insight protocol for CNS assessment of ifosfamide-handling pharmacists (no OEL trigger); chloroacetaldehyde cross-reference: absent; methylene blue preparedness: stocked at CHOP for patient ifosfamide encephalopathy treatment, but no occupational chloroacetaldehyde monitoring program for pharmacy staff; 36F pharmacist — H360 reproductive toxicant absent from EHS Insight output; eight years of VDC/IE preparation with zero EHS Insight annotation for any of the four cytotoxic components).

Integrating Glyphward into Ifosfamide and ICE Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ifosfamide CAS 3778-73-2 monitoring data ingestion point — before Cority at Fresenius Kabi USA LLC Wilson NC, before VelocityEHS at Hikma Pharmaceuticals USA Inc. Columbus OH, and before EHS Insight at The Children's Hospital of Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null + NIOSH HD Category 1 invisible + constitutional isomer identity confusion (same C7H15Cl2N2O2P/MW 261.09; divergent CYP3A4 vs CYP2B6 activation; divergent chloroacetaldehyde CNS vs acrolein urotoxic endpoints; both null) + chloroacetaldehyde CAS 107-20-0 CNS occupational gap (CYP3A4 N-dechloroethylation; OSHA ceiling 1 ppm for chloroacetaldehyde not cross-referenced in ifosfamide null output) + ICE protocol HD null chain (ifosfamide + carboplatin + etoposide [Attack #434]; NHL salvage) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + IARC Group 1 + pediatric solid tumor protocols (Ewing's/rhabdomyosarcoma standard of care; high-dose ifosfamide regimens; children's oncology = highest-volume ifosfamide pharmacy) + CYP3A4 drug interaction complexity (antifungal azoles [voriconazole, fluconazole] reduce CYP3A4 → reduce chloroacetaldehyde; CYP3A4 inducers increase it; this ratio clinically determines encephalopathy risk) [5 pts]; Fresenius Kabi USA LLC Wilson NC + Hikma Pharmaceuticals USA Inc. Columbus OH + The Children's Hospital of Philadelphia PA [3 pts]; FIRST ifosfamide HD null standalone; FIRST constitutional isomer confusion; FIRST chloroacetaldehyde CNS occupational gap; FIRST ICE protocol HD null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ifosfamide(cas: str, reading_ugm3: float, cyp3a4_inhibitor: bool = False) -> dict:
    """Scan ifosfamide HD Category 1 with chloroacetaldehyde CNS gap and isomer confusion."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                            # "3778-73-2" (ifosfamide)
                "reading_ugm3": reading_ugm3,
                "cyp3a4_inhibitor_coprescribed": cyp3a4_inhibitor,
                "context": "hd_alkylating_prodrug_isomer"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, activation_enzyme,
    #                    chloroacetaldehyde_metabolite_cas, osha_chloroacetaldehyde_ceiling_ppm,
    #                    constitutional_isomer_cyclophosphamide_cas, divergent_endpoint,
    #                    ice_null_chain_compounds, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_ifosfamide("3778-73-2", 0.0022, cyp3a4_inhibitor=True))
    print(r)
    # {'hd_category': 1, 'activation_enzyme': 'CYP3A4/CYP3A5',
    #  'chloroacetaldehyde_metabolite_cas': '107-20-0', 'osha_ceiling_ppm': 1.0,
    #  'constitutional_isomer': 'cyclophosphamide-50-18-0',
    #  'divergent_endpoint': 'chloroacetaldehyde_CNS_encephalopathy_not_acrolein_cystitis',
    #  'ice_null_chain': ['carboplatin-41575-94-4', 'etoposide-33419-42-0'],
    #  'usp800_required': True}